360° SearchNetwork Hot Spots Trends Time Series

Prolia

Type: Product

Name: Prolia

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Giving teriparatide with denosumab improves bone density

Combining teriparatide (Forsteo) with denosumab (Prolia) increases bone mineral density (BMD) in postmenopausal women with osteoporosis more than either drug alone, according to research published online in The Lancet. Moreover, the increases seen were ... [Published Pharmacy Magazine - May 16 2013]

Entities: Teriparatide, Denosumab, Density, Forsteo, Prolia

First reported May 14 2013 - Updated May 15 2013 - 3 reports

2-osteoporosis drug combo increases bone density better than single-drug therapy

Washington, May 15 (ANI): Researchers have claimed that a combination of two FDA-approved osteoporosis drugs having different mechanisms of action increases bone density better than treatment with either drug alone.The Massachusetts General Hospital (MGH) ... [Published News Track India - May 15 2013]

Entities: Teriparatide, Density, Denosumab, Drugs

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Enbrel

Amgen, Inc. (AMGN): What’s Its Next Catalyst?

Amgen, Inc. (NASDAQ: AMGN ) stock has been on a bit of a roller coaster lately. Shares are up 23% year to date, but 8% off the high set earlier this month before the company reported first-quarter earnings.It wasn’t prettyAdjusted earnings per share was ... [Published InsiderMonkey.com - May 02 2013]

Entities: Amgen Inc, Catalyst, Enbrel, HUMIRA, Drugs

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Manufacturing

Stability Despite Decline?

On average, salaries are healthy, and employment is stable. Respondents to this years survey report an average annual salary of $104,000 and an average raise of 4.1%. The average respondent has been employed in the industry for just over 16 years and ... [Published Pharmaceutical & Medical Packaging News - May 01 2013]

Entities: Medical Devices, Andrew Humphreys, Manufacturing

First reported Apr 30 2013 - Updated May 01 2013 - 1 reports

What News Will Drive Amgen Stock Next?

Keep track of the stocks that matter to you.Help yourself with the Fool's FREE and easy new watchlist service today. It wasn't prettyAdjusted earnings per share was up 22% year over year, but the long-term health of a biotech company is always going to ... [Published Motley Fool - Apr 30 2013]

Entities: Amgen Inc, watchlist, XGEVA, Biotechnology, Prolia

First reported Apr 24 2013 - Updated Apr 24 2013 - 2 reports

Amgen sales up for the quarter, but biosimilars grab buzz

Amgen's first-quarter revenues were up 5% over last year to $4.2 billion, with particular strength provided by biologics Enbrel, Xgeva and Prolia. The company's nascent biosimilars pipeline drew a significant amount of interest during the Q&A that followed ... [Published Medical Marketing And Media - Apr 24 2013]

Entities: Prolia, Amgen Inc, XGEVA

First reported Apr 22 2013 - Updated Apr 23 2013 - 1 reports

Amgen Inc

Will Amgen Beat Earnings?

We expect Amgen Inc. (AMGN) to beat earnings expectations when it reports first-quarter 2013 results after the closing bell on Apr 23, 2013.Why a Likely Positive Surprise?Our proven model shows that Amgen has the right combination of two key ingredients ... [Published Yahoo! Finance - Apr 22 2013]

Entities: Amgen Inc, XGEVA, Prolia

First reported Apr 19 2013 - Updated Apr 19 2013 - 2 reports

Hated German price formula to be applied to Pradaxa, Prolia, other drugs

Agency will evaluate 10 drugs in 6 treatment categories with eye to roll back pricesShareToolsDrugmakers, livid with German pricing gatekeepers for turning down so many new drugs, now face a strategy that is sure to ratchet up their anger to the boiling ... [Published FiercePharma - Apr 19 2013]

Entities: Pradaxa, Prolia, Drugs, IQWiG

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Bayer, Amgen Face Price Cuts as German Panel Expands Drug Review

Bayer AG (BAYN) and Amgen Inc. (AMGN) are among drugmakers who may face price cuts as a German agency begins a broader review of the costs and benefits of medicines already on the market.Bayer’s blood thinner Xarelto, Amgen’s Prolia for osteoporosis and ... [Published PharmaGossip - Apr 19 2013]

Entities: Amgen Inc, Bayer AG, Pradaxa, blood thinner, Xarelto

First reported Apr 01 2013 - Updated Apr 01 2013 - 1 reports

Four Factors Driving Amgen's Stock Price To $102

By Bio Vantage : The stock price of Amgen ( AMGN ) has advanced from $88 to $102 since we covered it last November ( Amgen: Equity Report And Stock Valuation ). This translates to a decent 16% increase in just four months. In that report, we had derived ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 01 2013]

Entities: XGEVA, Prolia, Amgen Inc, Revenue Growth

First reported Mar 06 2013 - Updated Mar 06 2013 - 1 reports

Teva Joins Top 10, “Face” of Big Pharma Changing

Teva’s accession to the exclusive group that is the Pharma Top 10 is further proof, according to IMS Health, that branded pharma needs to renounce its product-protected past and embrace the patient-led, specialty-focused future.As the first non-western, ... [Published Pharmaceutical Executive - Mar 06 2013]

Entities: Big Pharma, IMS Health Inc, Gilenya, Roche Holding AG, Novartis AG

First reported Feb 19 2013 - Updated Feb 19 2013 - 1 reports

Drug Costs In Hospitals & Clinics To Rise 4 Percent

The cost of medications administered by clinics and hospitals are expected to rise by as much as 4 percent this year, which is less than in previous years, thanks to the increasing availabitily of lower-cost generics, according to a study in the American ... [Published Pharmalot - Feb 19 2013]

Entities: Drugs, epoetin alfa, infliximab, Immunoglobulin

Quotes

"Our results demonstrate that the combination of denosumab and teriparatide increases bone density more than either individual therapy, most likely because denosumab is able to potently block bone resorption even when given along with a bone-building agent like teriparatide [which has been shown to interfere with the suppression of bone resorption in previous studies]."

Giving teriparatide with denosumab improves bone density [Published Pharmacy Magazine - May 16 2013]

The authors of a linked comment, Richard Eastell and Jennifer Walsh, of the Mellanby Centre for Bone Research, University of Sheffield, say: "Whether the combination remains effective needs to be investigated, however, because at 12 months mean concentrations of the bone formation marker PINP no longer differed between the denosumab-alone and combination-therapy groups. The safety of this combination therapy also needs to be explored, as does what happens when teriparatide is stopped (the licence only supports use for a maximum of 24 months). Finally, the reduction in fracture risk needs to be quantified so that cost-effectiveness can be assessed."

Giving teriparatide with denosumab improves bone density [Published PJ Online - May 15 2013]

"Talk to your doctor about how to build strong bones."

Rx Tag-Team Works Better for Weak Bones [Published Daily Rx - May 15 2013]

"A combination of these two medications increased bone density more than either does on its own, and it is more effective than any currently approved therapy" said study author Dr. Benjamin Leder, who is with the endocrine unit at Massachusetts General Hospital in Boston

Combo Drug Therapy May Work Best to Strengthen Bones: Study [Published Bio-Medicine - May 15 2013]

More Content

sort by: Date \| Relevance
Giving teriparatide with denosumab improves bon... [Published Pharmacy Magazine - May 16 2013]
Study: Treatment With Two Osteoporosis Drugs Be... [Published PT Community - May 15 2013]
Drug combination offers hope for osteoporosis [Published Hampshire Chronicle - May 15 2013]
Giving teriparatide with denosumab improves bon... [Published PJ Online - May 15 2013]
2-osteoporosis drug combo increases bone densit... [Published News Track India - May 15 2013]
Rx Tag-Team Works Better for Weak Bones [Published Daily Rx - May 15 2013]
Combo Drug Therapy May Work Best to Strengthen ... [Published Bio-Medicine - May 15 2013]
Teriparatide/denosumab superior to monotherapy ... [Published Orthopedics Today - May 14 2013]
Treatment with 2 osteoporosis drugs better at i... [Published EurekAlert! - May 14 2013]
New osteoporosis drug combination outperforms c... [Published Medical Xpress - May 14 2013]
Forteo Plus Prolia Builds Bone [Published MedPage Today - May 14 2013]
Amgen Chased By The Bubble [Published Investopedia - May 11 2013]
Amgen aims to restock its medicine cabinet [Published Los Angeles Times - May 06 2013]
Amgen, Inc. (AMGN): What’s Its Next Catalyst? [Published InsiderMonkey.com - May 02 2013]
Stability Despite Decline? [Published Pharmaceutical & Medical Packaging News - May 01 2013]
What News Will Drive Amgen Stock Next? [Published Motley Fool - Apr 30 2013]
Amgen sales up for the quarter, but biosimilars... [Published Medical Marketing And Media - Apr 24 2013]
Tax Benefit Boosts Amgen Earnings Zacks [Published Yahoo! Finance - Apr 24 2013]
The Zacks Analyst Blog Highlights: Amgen, Freep... [Published Yahoo! Finance - Apr 23 2013]
ARGEN-X Appoints Dr. David Lacey to its Supervi... [Published Thuja Capital - Apr 23 2013]
Will Amgen Beat Earnings? - Analyst Blog [Published Zacks.com - Apr 22 2013]
Will Amgen Beat Earnings? [Published Yahoo! Finance - Apr 22 2013]
Amgen Inc. (AMGN) - Financial and Strategic SWO... [Published TransWorldNews - Apr 21 2013]
PharmaPoint: Osteoporosis - US Drug Forecast an... [Published Live-PR.com - Apr 21 2013]
Fitch Affirms Amgen's IDR at 'BBB'; Ratings Out... [Published Yahoo! Finance - Apr 19 2013]
Fitch Affirms Amgen's IDR at 'BBB'; Ratings Out... [Published Business Wire - Apr 19 2013]
Amgen Earnings Report Due Tuesday [Published Drug Discovery and Development - Apr 19 2013]
Hated German price formula to be applied to Pra... [Published FiercePharma - Apr 19 2013]
Germany looks at price cuts on big-selling drugs [Published Pharma Times - Apr 19 2013]
Earnings Preview: Amgen reports 1Q results Tuesday [Published Equities.com - Apr 19 2013]

Blogs

sort by: Date \| Relevance
Bayer, Amgen Face Price Cuts as German Panel Ex... [Published PharmaGossip - Apr 19 2013] Bayer AG (BAYN) and Amgen Inc. (AMGN) are among drugmakers who may face price cuts as a German agency begins a broader review of the costs and benefits of medicines already on the market.Bayer’s blood thinner Xarelto, Amgen’s Prolia for osteoporosis and ...
Merck Taps Perlmutter To Replace Kim To Run R&D [Published Pharmalot - Mar 07 2013] After a decade filled with more disappointments that stellar successes, Merck announced that R&D chief Peter Kim is retiring and will be replaced by Roger Perlmutter, who had aspired to the job before leaving the big drugmaker in 2001 to run R&D operations ...
Drug Costs In Hospitals & Clinics To Rise 4 Per... [Published Pharmalot - Feb 19 2013] The cost of medications administered by clinics and hospitals are expected to rise by as much as 4 percent this year, which is less than in previous years, thanks to the increasing availabitily of lower-cost generics, according to a study in the American ...
Time to Refill Your Prescription For Zxygjfb [Published In the Pipeline - Jan 28 2013] The brand names of drugs are famously odd. But they seem to be getting odder. That's the conclusion of a longtime reader, who sent this along: I was recently perusing through the recent drug approval list and was struck by how strange the trade names ...
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Nov 21 2012]

Press Releases

sort by: Date \| Relevance
Fitch Affirms Amgen's IDR at 'BBB'; Ratings Out... [Published Business Wire - Apr 19 2013]